The fiducial markers market size was exhibited at USD 154.16 million in 2024 and is projected to hit around USD 414.63 million by 2034, growing at a CAGR of 10.4% during the forecast period 2024 to 2034.
| Report Coverage | Details |
| Market Size in 2025 | USD 170.19 Million |
| Market Size by 2034 | USD 414.63 Million |
| Growth Rate From 2024 to 2034 | CAGR of 10.4% |
| Base Year | 2024 |
| Forecast Period | 2024-2034 |
| Segments Covered | Product, Modality, Application, End-user, and Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Covered | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | CIVCO Radiotherapy; IZI Medical Products; Naslund Medical AB; Medtronic PLC; QlRad, Inc.; QFIX; Boston Scientific Corp.; Nanovi A/S; Eckert & Ziegler; IBA Dosimetry GmbH |
Growing incidence of various types of cancer such as lung, prostate, and breast, and increasing adoption of radiotherapy for oncology treatments is expected to contribute to the market growth.
Fiducial markers are placed in or near a tumor during the radiotherapy procedure to locate the tumor for providing accurate radiation dosage. There have been several technological advancements to develop an advanced navigation system for proper placement of the product. For instance, SPiN System’s advanced navigation technology by Veran Medical Technologies helps locate the target to place the fiducial marker appropriately for radiation or resection. This technology also provides a 3D view of fiducials and generates the report for proper diagnosis and treatment.
Growing awareness about targeted radiotherapy techniques, such as image-guided radiotherapy, intensity-modulated radiotherapy, and stereotactic radiosurgery, is expected to contribute to the adoption of fiducial markers. Owing to the complications and adverse effects associated with chemotherapy and targeted drug therapy, preference for radiotherapy is expected to show a steep rise during the forecast period.
Radiotherapy is recommended as a parallel or palliative therapy with other treatment procedures for various types of cancers. For instance, in breast cancer (stage 1 and 2), most of the patients are prescribed with breast-conserving surgery and radiotherapy sessions. In addition, increased funding by various governments and social organizations for the research related to fiducial markers and cancer is expected to spur the market growth.
However, complications associated with product implantation and usage may hinder its adoption. As per NCBI, patients who underwent transrectal fiducial marker insertion for prostate cancer image-guided therapy suffered from Haematuria, haematospermia rectal bleeding, and dysuria.
Based on the product, the market is segmented into gold, gold combination, polymer, other metals, and liquid. The gold segment held the largest share in 2024 owing to the accurate visibility and superior stability of these products across several imaging modalities. Gold fiducial markers also come in combination with other metals, such as titanium, platinum, and nickel, for enhanced efficiency. For instance, when combined with titanium stripes, these markers enhance the visibility in MRI images.
Major companies are investing more in R&D to design products with improved efficiency. For instance, IBA Dosimetry GmbH launched a linear pure gold fiducial marker called Visicoil, a unique helical-shaped product with a hollow core that reduces the incidence of common complications, such as marker migration and artifacts. The polymer segment is also expected to register significant growth over the forecast period. The lower cost of these products than other metal markers is expected to contribute to the segment growth. On the other hand, liquid fiducial markers are expected to experience the fastest CAGR during the forecast period.
Based on modality, the market is segmented into CT/CBCT, ultrasound, X-ray, and MRI. The CT/CBCT segment held the largest market share in 2024 and is expected to register a healthy CAGR over the forecast period. Low dose exposure, ease of integration with existing radiotherapy equipment, and orthogonal imaging features of CBCT are the major factors contributing to the segment growth.
The ultrasound modality segment is expected to experience the fastest CAGR over the forecast period. Lower radiation toxicity of this modality than other imaging modalities is the key factor contributing to the segment growth. Moreover, the ability of fiducial markers with ultrasound modality to provide real-time volumetric information with organ tracking makes them suitable for monitoring inter and intrafraction organ motion, due to which they are widely used in the treatment of breast, prostate, and liver cancer.
The MRI modality segment is expected to register notable growth during the forecast period. Fiducial markers with MRI modality provide reliable and accurate details of the soft tissues during the treatment of complex cases, such as orthotopic prostate tumors. Furthermore, the growing adoption of an MRI-based LINAC system is expected to boost the segment growth.
The prostate cancer segment held the largest market share in 2024 and is projected to expand further at a healthy CAGR over the forecast period. Growing product adoption in the treatment of prostate cancer is the key factor driving the segment growth. The lung cancer segment is expected to witness the fastest growth during the forecast period.
Factors responsible for the segment growth include rising incidence of lung cancer and technological advancements for the development of enhanced fiducial markers for better treatment of the disease. For instance, Beacon FNF by Medtronic PLC is a pre-loaded gold fiducial marker system that reduces the risk of commonly reported complications, such as pneumothorax, to a greater extent.
The breast cancer segment is also expected to register a significant CAGR over the forecast period. Rising awareness about the efficiency of external beam radiation therapy in the treatment of breast cancer and increased funding are the factor projected to foster the segment growth.
Based on end users, the market is segmented into hospitals, radiotherapy centers, and academic research centers. The hospital segment held the largest market share in the past. The availability of advanced radiotherapy equipment in these healthcare settings is expected to contribute to segment growth. The radiotherapy centers segment held the second-largest market share and is expected to register the fastest CAGR over the forecast period. Rising preference for radiotherapy centers over hospitals is boosting segment growth.
Academic and research centers is anticipated to be the second fastest-growing segment during the forecast period. Active participation of federal and non-government organizations to develop strategies to deliver efficient cancer care has resulted in an increasing number of public and government funding in cancer research, driving segment growth. For instance, in 2024, the NIH and NCI will receive public funding of USD 39.1 billion and USD 6.14 billion, respectively, for cancer research.
North America held the largest share of the global market in 2024. The strong presence of major market participants, streamlined reimbursement policies, and public health programs are the key factors expected to drive the region’s growth. Moreover, the rising adoption of advanced radiotherapy procedures and imaging modalities will boost the product demand in the region, thereby supporting market growth.
Europe held the second-largest market share in 2024. In Europe, over 3.2 million people are diagnosed with cancer every year. Breast and colorectal cancer are the most prevalent due to the increasing aging population and rising cases of obesity. In addition, increasing CE approval of various fiducial markers is also expected to contribute to the regional market growth. For example, in March 2021, liquid fiducial marker BioXmark by Nanovi A/S received CE approval.
The Asia Pacific is expected to register the fastest growth over the forecast period. Highly unmet clinical needs, coupled with increasing number of cancer care initiatives, especially in China and India, are expected to boost the region’s growth. For instance, in 2024, the Chinese government relieved additional tax on 16 imported goods, which also include medical LINAC systems.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the fiducial markers market
By Product
By Modality
By Application
By End-user
By Regional
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Modality
1.1.3. Application
1.1.4. End-user
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Modality outlook
2.2.3. Application outlook
2.2.4. End-user outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. Fiducial Markers Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Increasing prevalence of cancer
3.4.1.2. Rising acceptance of radiotherapy procedures
3.4.1.3. Increasing public and private funding in cancer research
3.4.2. Market restraint analysis
3.4.2.1. Availability of alternate treatment options
3.4.2.2. Lack of skilled professionals
3.5. Fiducial Markers Market Analysis Tools
3.5.1. Industry analysis – Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
3.5.3. Major deals & strategic alliances analysis
3.5.4. Market entry strategies
Chapter 4. Global Fiducial Markers Market: Product Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Gold
4.1.2. Gold Combination
4.1.3. Polymer
4.1.4. Other Metal
4.1.5. Liquid
4.2. Product Market Share, 2024 & 2034
4.3. Segment Dashboard
4.4. Global Fiducial Markers Market by Product Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2021 to 2034 for the following
4.5.1. Gold
4.5.1.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million, Volume, Units)
4.5.2. Gold Combination
4.5.2.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million, Volume, Units)
4.5.3. Polymer
4.5.3.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million, Volume, Units)
4.5.4. Other Metals
4.5.4.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million, Volume, Units)
4.5.5. Liquid
4.5.5.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million, Volume, Units)
Chapter 5. Global Fiducial Markers Market: Modality Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. CT/CBCT
5.1.2. MRI
5.1.3. Ultrasound
5.1.4. X-Ray
5.2. Modality Share, 2024 & 2034
5.3. Segment Dashboard
5.4. Global Fiducial Markers Market by Modality Outlook
5.5. Market Size & Forecasts and Trend Analyses, 2021 to 2034 for the following
5.5.1. CT/CBCT
5.5.1.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
5.5.2. MRI
5.5.2.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
5.5.3. Ultrasound
5.5.3.1. Market estimates and forecast, 2021 - 2034 (USD Million)
5.5.4. X-Ray
5.5.4.1. Market estimates and forecast, 2021 - 2034 (USD Million)
Chapter 6. Global Fiducial Markers Market: Application Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Breast Cancer
6.1.2. Lung Cancer
6.1.3. Prostate Cancer
6.1.4. Head and Neck Cancer
6.1.5. Other
6.2. Application Share, 2024 & 2034
6.3. Segment Dashboard
6.4. Global Fiducial Markers Market by Application Outlook
6.5. Market Size & Forecasts and Trend Analyses, 2021 to 2034 for the following
6.5.1. Breast cancer
6.5.1.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
6.5.2. Lung cancer
6.5.2.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
6.5.3. Prostate cancer
6.5.3.1. Market estimates and forecast, 2021 - 2034 (USD Million)
6.5.4. Head and neck cancer
6.5.4.1. Market estimates and forecast, 2021 - 2034 (USD Million)
6.5.5. Others
6.5.5.1. Market estimates and forecast, 2021 - 2034 (USD Million)
Chapter 7. Global Fiducial Markers Market: End-User Estimates & Trend Analysis
7.1. Definitions and Scope
7.1.1. Hospitals
7.1.2. Radiotherapy Center
7.1.3. Academic and Research Center
7.2. End-User, 2024 & 2034
7.3. Segment Dashboard
7.4. Global Fiducial Markers Market by End-user Outlook
7.5. Market Size & Forecasts and Trend Analyses, 2021 to 2034 for the following
7.5.1. Hospitals
7.5.1.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
7.5.2. Radiotherapy Center
7.5.2.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
7.5.3. Academic and Research Center
7.5.3.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
Chapter 8. Global Fiducial Markers Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2034
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Regional Market Share and Leading Players, 2019
8.4.1. North America
8.4.2. Europe
8.4.3. Asia Pacific
8.4.4. Latin America
8.4.5. Middle East and Africa
8.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
8.5.1. North America
8.5.2. Europe
8.5.3. Asia Pacific
8.5.4. Latin America
8.5.5. Middle East and Africa
8.6. Market Size, & Forecasts, Volume and Trend Analysis, 2019 to 2027:
8.7. North America
8.7.1. U.S.
8.7.1.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.7.2. Canada
8.7.2.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.8. Europe
8.8.1. U.K.
8.8.1.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.8.2. Germany
8.8.2.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.8.3. France
8.8.3.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.8.4. Italy
8.8.4.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.8.5. Spain
8.8.5.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.8.6. Russia
8.8.6.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.8.7. Switzerland
8.8.7.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.8.8. The Netherlands
8.8.8.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.8.9. Sweden
8.8.9.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.8.10. Belgium
8.8.10.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.9. Asia Pacific
8.9.1. Japan
8.9.1.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.9.2. China
8.9.2.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.9.3. India
8.9.3.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.9.4. South Korea
8.9.4.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.9.5. Thailand
8.9.5.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.9.6. Indonesia
8.9.6.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.9.7. Philippines
8.9.7.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.9.8. Taiwan
8.9.8.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.9.9. Malaysia
8.9.9.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.9.10. Singapore
8.9.10.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.10. Latin America
8.10.1. Brazil
8.10.1.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.10.2. Mexico
8.10.2.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.10.3. Argentina
8.10.3.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.10.4. Colombia
8.10.4.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.10.5. Chile
8.10.5.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.11. MEA
8.11.1. South Africa
8.11.1.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.11.2. Saudi Arabia
8.11.2.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.11.3. UAE
8.11.3.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.11.4. Kuwait
8.11.4.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
8.11.5. Israel
8.11.5.1. Market estimates and forecast, 2021 - 2034 (Revenue, USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competitive Categorization
9.2.1. Innovators
9.2.2. Market leaders
9.2.3. Emerging players
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company market share analysis, 2019
9.4. Public Companies
9.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
9.4.2. Company market share/ranking, by region
9.4.3. Competitive dashboard analysis
9.4.3.1. Market differentiators
9.4.3.2. Synergy analysis: major deals and strategic alliances
9.5. Private Companies
9.5.1. List of key emerging companies/technology disruptors/innovators
9.5.2. Funding outlook
9.5.3. Regional network map
9.5.4. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
9.5.5. Supplier ranking
9.5.6. Key company profiled
9.5.7. CIVCO Radiotherapy
9.5.7.1. Company overview
9.5.7.2. Financial performance
9.5.7.3. Product benchmarking
9.5.7.4. Strategic initiatives
9.5.8. IZI Medical Products
9.5.8.1. Company overview
9.5.8.2. Financial performance
9.5.8.3. Product benchmarking
9.5.8.4. Strategic initiatives
9.5.9. Naslund Medical AB
9.5.9.1. Company overview
9.5.9.2. Financial performance
9.5.9.3. Product benchmarking
9.5.9.4. Strategic initiatives
9.5.10. Medtronic, Inc.
9.5.10.1. Company overview
9.5.10.2. Financial performance
9.5.10.3. Product benchmarking
9.5.10.4. Strategic Initiative
9.5.11. QlRad Inc.
9.5.11.1. Company overview
9.5.11.2. Financial performance
9.5.11.3. Product benchmarking
9.5.11.4. Strategic initiatives
9.5.12. QFix
9.5.12.1. Company overview
9.5.12.2. Financial performance
9.5.12.3. Product benchmarking
9.5.12.4. Strategic initiatives
9.5.13. Boston Scientific Corporation
9.5.13.1. Company overview
9.5.13.2. Financial performance
9.5.13.3. Product benchmarking
9.5.13.4. Strategic initiatives
9.5.14. Nanovi A/S
9.5.14.1. Company overview
9.5.14.2. Financial performance
9.5.14.3. Product benchmarking
9.5.14.4. Strategic initiatives
9.5.15. Eckert & Ziegler
9.5.15.1. Company overview
9.5.15.2. Financial performance
9.5.15.3. Product benchmarking
9.5.15.4. Strategic initiatives
9.5.16. IBA Dosimetry GmbH
9.5.16.1. Company overview
9.5.16.2. Financial performance
9.5.16.3. Product benchmarking
9.5.16.4. Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers